Genus (LSE:GNS) has a catalyst few other FTSE 250 companies can point to: a gene-edited pig designed to resist one of the most costly diseases in pork production. Its PRRS-Resistant Pig (PRP) has now received approvals or positive determinations in Argentina, Canada, Uruguay and Peru, and commercialisation is beginning in selected Latin American countries.
That development arrives alongside a strong set of full-year numbers. In preliminary results published on 10 September 2026 for the year to 30 June 2026, adjusted profit before tax rose 35% to £100.2m and adjusted Basic Earnings Per Share also climbed 35% to 110.3p, even though Revenue dipped 2% to £658.1m.
The group has also reshaped its China exposure, forming a porcine joint venture with Beijing Capital Agribusiness (BCA), and announced a new £60m share buyback to be completed during its 2027 financial year. Together, these moves give the company both a scientific and a financial story to tell.
A global animal genetics business
Genus describes itself as a leading global animal genetics company. It operates through two main businesses: PIC, which supplies porcine genetics to pork producers, and ABS, which provides bovine genetics to dairy and beef farmers.
Both businesses sell improved genetics that help customers raise productivity, animal health and efficiency. PIC's model includes Royalty revenue from customers, which gives the Business a recurring income element. The group's financial year ends on 30 June.
Animal genetics is a long-cycle industry. Improvements bred into breeding stock accumulate over generations, which can create durable competitive advantages, but also means new products such as PRP take years to move from research to commercial scale.
FY26 results, a higher Dividend and a new buyback
Genus had already signalled a strong finish. Its trading update on 14 July 2026 said the second half had been better than anticipated and that FY26 results would be moderately ahead of consensus.
The preliminary results confirmed that picture. Adjusted operating profit rose 17% to £94.8m, or 25% to £116.0m including joint ventures. Excluding BCA milestone payments, adjusted profit before tax still increased 34%. Free Cash Flow improved to £62.0m from £40.9m.
Statutory figures were boosted by one-off items. Statutory profit before tax was £310.5m, including a £204.1m gain from the disposal of 51% of PIC China into the joint venture and a £12.8m IAS 41 uplift on biological assets. Statutory earnings per share were 431.6p.
The board has proposed a final dividend of 24.0p, up 11%, taking the full-year dividend to 35.2p, a 10% increase. That represents a 32% payout ratio, within the company's 30–40% policy range.
The Balance Sheet has strengthened markedly. Leverage fell to 0.4 times from 1.5 times, helped by the China proceeds. Alongside the results, the company announced a new £60m share buyback, which it intends to complete during FY27.
PIC and ABS: divergent drivers
PIC was the main engine of growth. Volumes including joint ventures rose 12%, royalty revenue increased 1% to £179m and adjusted royalty revenue grew 5% to £196.9m. Adjusted operating profit including joint ventures rose 17% to £130.8m. Strength in Asia, including China, and Latin America offset weaker North America, where customers faced disease challenges.
ABS delivered double-digit profit growth despite softer Demand and lower global dairy prices. Volumes rose 1% and sexed genetics volumes increased 2%, while adjusted operating profit including joint ventures reached £22.9m, a Margin of 7.6%. The improvement was driven by the Value Acceleration Programme, whose third phase has now been completed, delivering £7m of benefit in the year and £9m on an annualised basis.
The gene-edited pig and the China joint venture
PRRS, or porcine reproductive and respiratory syndrome, is a viral disease that causes significant losses for pig farmers worldwide. A pig that is resistant to it could offer meaningful benefits for animal welfare and producer economics, which is why regulatory progress on PRP is closely watched.
Approvals or positive determinations in Argentina, Canada, Uruguay and Peru mark concrete progress, and the start of commercialisation in selected Latin American markets moves PRP from a development programme towards a revenue opportunity. Wider adoption will depend on further regulatory decisions and on how the food Supply chain responds to gene-edited products.
In China, Genus (LSE:GNS) formed its porcine joint venture with BCA in January 2026, with formation announced on 2 February 2026. The company received around £111m of net cash consideration from BCA in the fourth quarter, and reported £98m of net cash from the PIC China sale in its results. Having sold 51% of PIC China into the venture, Genus now shares ownership of its Chinese porcine business with a local partner, a structure that can help navigate a large and complex market.
Risks to weigh
Disease remains a double-edged factor. Customer disease challenges weighed on North America this year, and outbreaks can disrupt demand in any region. For ABS, dairy prices and farmer profitability influence demand for genetics.
PRP carries regulatory and market-acceptance risk. Approvals so far cover a limited number of countries and commercial uptake is only beginning, so the timing of adoption in other major pork markets is uncertain.
The China joint venture changes how Genus participates in that market, and reported profits now include joint venture contributions and milestone payments. Headline statutory profit was also flattered by one-off gains, so adjusted measures give a clearer view of underlying trading.
What to watch
Near-term, investors will follow execution of the £60m buyback through FY27 and whether PIC can sustain Volume growth while North American customers work through disease issues. Further delivery from the ABS Value Acceleration Programme will be key to margin progress.
The biggest swing Factor is PRP. Additional regulatory decisions, the pace of commercialisation in Latin America and any early evidence of customer adoption will shape how much value the market attributes to the gene-edited pig over time.
Conclusion
Genus closed FY26 with adjusted earnings up 35%, a stronger balance sheet after the China joint venture and higher Shareholder returns through dividends and a new buyback. Its gene-edited pig has moved into early commercialisation in parts of Latin America, giving the FTSE 250 company a distinctive long-term catalyst, albeit one whose full potential still depends on wider regulatory and market acceptance.
_11_19_2026_14_04_21_792016.jpg)
_11_19_2026_14_04_28_358813.jpg)




Please wait processing your request...